MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

804.64M

Vuru Grade

31.00/100

Current Price

$11.73
-0.14 (-1.18%)

Company Metrics

  • P/E 13.83
  • P/S 9.87
  • P/B 2.43
  • EPS -1.53
  • Cash ROIC -52.09%
  • Cash Ratio 9.03
  • Dividend 0 / N/A %
  • Avg. Vol. 550,081.00
  • Shares 68.60M
  • Market Cap. 804.64M

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Last Traded Price Fluctuations: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Street Updates - 8 hours ago
In the past trading session, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) highlighted downward shift of -1.82% or -0.22 points to $11.87.
Eagle Pharmaceuticals Inc versus Momenta Pharmaceuticals Inc Head to Head Compare
CML News - 4 hours ago
Eagle Pharmaceuticals Inc has a substantially higher fundamental rating then Momenta Pharmaceuticals Inc which has an impact on the head-to-head comparison.
Momenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors
GlobeNewswire (press release) - Sep 23, 2016
CAMBRIDGE, Mass., Sept. 23, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Corey N.
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) Receives $16.29 Consensus Target ... - BBNS
Why Momenta Pharmaceuticals, Inc. Was Up Today
Motley Fool - Jan 8, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) was up as much as much as 11.7% today, eventually finishing up 6.8% after announcing a deal with Mylan (NASDAQ:MYL) to develop six biosimilar products.
Momenta Pharmaceuticals Announces Worldwide Collaboration With Mylan to ... - GlobeNewswire (press release)
Momenta, Mylan to Jointly Develop Six Biosimilars - Wall Street Journal
Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February -- Here's Why
Motley Fool - Mar 4, 2016
What: Shares of Momenta Pharmaceuticals (NASDAQ:MNTA), a biopharmaceutical company focused on the development of generic and biosimilar drugs for oncology and autoimmune diseases, shed 33% of their value in February, based on data from S&P ...
Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?
Motley Fool - Aug 9, 2016
While the report included sales of Momenta's and partner Novartis AG's (NYSE:NVS) Glatopa, the generic version of Teva Pharmaceutical Industries' (NYSE:TEVA) once-daily Copaxone, investors should focus on the potential approval of the generic ...
Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today
Motley Fool - Feb 18, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) is down 11% at 12:00 p.m. EST Thursday after releasing fourth quarter earnings this morning.
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q4 2015 Results ... - Seeking Alpha
Here's Why Maxim Downgraded Momenta Pharmaceuticals, Inc. (MNTA) to Sell
Smarter Analyst - Sep 7, 2016
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares are tumbling 4% today, with sales for its generic copaxone (glatopa), an injection designed to treat patients with relapsing and remitting forms of multiple sclerosis (RRMS), failing to impress or even ...
Analysts Downgrade of the Day: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Review Fortune
Momenta Pharmaceuticals, Inc. 47.2% Potential Decrease Now Implied by Maxim Group - DirectorsTalk Interviews
Momenta Pharmaceuticals Inc versus Spectrum Pharmaceuticals Inc Head to Head ...
CML News - Sep 19, 2016
Momenta Pharmaceuticals Inc has a higher fundamental rating than Spectrum Pharmaceuticals Inc which has an impact on the head-to-head comparison.
Momenta Pharmaceuticals: Waiting for Fewer Injections
Motley Fool - May 9, 2016
The Motley Fool recommends Momenta Pharmaceuticals, Mylan, and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days.